Vericel combines rare biological moats, self-funded growth, and expanding cell-therapy markets into a high-quality but execution-sensitive compounding story.
Overview
Vericel is a specialized commercial-stage cell therapy company focused on sports medicine and severe burn care through MACI, Epicel, and NexoBrid. Its model combines high-margin, patient-specific manufacturing with strong clinical differentiation, favorable reimbursement, and dedicated specialty sales infrastructure. MACI is the core revenue engine, supported by superior long-term outcomes versus microfracture, while Epicel and NexoBrid provide life-saving burn-care solutions. The company is self-funded, debt-free, and positioned to scale through MACI Arthro adoption, burn-care expansion, and new manufacturing capacity.